Treatment of melanoma using HSV mutant
US8067012B2 · kind B2 · utility
0Cited by
5References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 22, 2010 |
| Grant date | Nov 29, 2011 |
| Priority date | — |
| Expiry date | Jan 22, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16632
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (RL) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.